stockrow
Saturday 7 November 2026
Export RANI’s income statement to Excel — free account
Rani Therapeutics Holdings, Inc.
RANI Healthcare Biotechnology
Rani Therapeutics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.6 million, up 58.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +77.8%
- Free cash flow
- −55.3%
Quarter to June 2026, against a year earlier
0.54
0.02
+3.85%
Follow RANI
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (155.24%) | (195.02%) | (131.87%) | 913.68% |
+8 more TTM periods Free account |
|
| (77.54%) | (77.47%) | (62.30%) | (105.50%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(64.95%) | (87.01%) | (71.69%) | 213.42% | |
Average Days of Receivables |
147.62 | 223.09 | 207.38 | — | |
Free Cash Flow per Share |
(0.11) | (0.10) | (0.28) | (0.60) | |
Free Cash Flow |
(20.34) | (17.11) | (18.80) | (27.78) | |
Capital Expenditures |
(0.05) | (0.05) | (0.09) | (0.12) | |
| Other line items | |||||
Cash ROIC |
(20.06%) | (21.68%) | (20.61%) | (486.72%) | |
Accounts Receivable Turnover |
2.13 | 2.98 | 3.32 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
362.61% | 562.59% | 562.19% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
386.77% | 568.96% | 549.19% | 0.00% | |
Share Based Compensation of Revenue |
180.02% | 298.02% | 328.27% | 0.00% | |
Interest Coverage |
(28.24) | (17.01) | (13.25) | (12.19) | |
Operating CF/Net income |
0.67 | 0.58 | 0.63 | 0.98 | |
Depreciation/Fixed assets |
0.35 | 0.98 | 1.13 | 0.81 | |
Capex/Depreciation |
(0.26) | (0.09) | (0.11) | (0.16) | |
Revenue per Share |
0.03 | 0.02 | 0.05 | 0.00 | |
Operating CF per Share |
(0.11) | (0.09) | (0.28) | (0.60) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.00 |
Columns are period end dates